The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories · page 2 of 23

Stories

  1. Ribupatide shows significant weight loss in adults without diabetes

    In a phase 3 trial of 567 participants, once-weekly ribupatide produced least-squares mean weight reductions of -10.7%, -16.4%, and -17.7% at 48 weeks for 2, 4, and 6 mg doses versus -1.4% with placebo. Gastrointestinal events were the most frequent adverse events, occurring in 47.9%, 58.2%, and 63.1% of participants at the three doses.

  2. Among industry trials that gave a stop reason, 6 in 10 now cite a sponsor or business decision, up from 3 in 10

    A Priority Review analysis of 18,422 terminated trials on ClinicalTrials.gov. Among industry trials that gave a stop reason, 63.5% of those ended in 2025 cited a sponsor or business decision (407 of 641), up from 31.5% in 2016 (107 of 340). Enrollment fell from 31.8% to 12.3% on the same basis.

  3. Nearly 1 in 5 recruiting US trials for adults exclude people 80 and older by rule

    The FDA's new draft guidance says early-phase solid tumor trials should in general set no upper age limit, and most already set none. A Priority Review analysis of 11,830 recruiting US trials finds the limits elsewhere: 41.8% of mental health trials and 38.3% of metabolic trials exclude people 80 and older.

  4. Lilly presents new data on Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026

    Lilly will present Phase 2 data showing EloraTZP achieved an average weight loss of 54.1 lbs (23.3%) and lowered A1C by 2.9% in adults with obesity or overweight and type 2 diabetes. Retatrutide results from TRIUMPH trials demonstrated reductions in apnea-hypopnea index and knee osteoarthritis pain up to 36.1 events per hour and 4.5 points, respectively.

  5. 104 of 119 adults with hypersomnia had treatment-emergent adverse events on pitolisant

    Treatment-emergent adverse events were reported for 104 of 119 adults with idiopathic hypersomnia receiving pitolisant. Long-term safety data and sleepiness scores are now available for participants from a randomized withdrawal study.

  6. Novatek registers Phase 2/3 trial of NP-101 in GEP-NECs

    The study, led by Novatek Pharmaceuticals, plans to enroll an estimate of 381 participants to evaluate the safety and efficacy of NP-101 combined with Nivolumab and Ipilimumab versus placebo in refractory advanced and metastatic gastroenteropancreatic neuroendocrine carcinomas. It is planned to begin in January 2027 and reach primary completion in December 2029.

  7. AstraZeneca registers Phase 3 trial of Symbicort Aerosphere in children

    The study plans to enroll 216 participants aged 4 to <12 years and start on October 30, 2026. It plans to compare BFF MDI 80/4.8 μg 2 actuations BID to BD MDI 80 μg 2 actuations BID over 6 weeks to assess lung function and safety.

  8. RemeGen registers Phase IIIb trial of RC28-E Injection in DME and wAMD

    The study, led by RemeGen Co., Ltd., plans to enroll 350 participants and has a planned start date of October 30, 2026. It aims to evaluate the safety profile and explore the efficacy of RC28-E in participants with diabetic macular edema and wet age-related macular degeneration.

  9. RemeGen registers Phase II/III study of RC118 plus RC148 for claudin 18.2-positive gastric cancer

    The study, led by RemeGen Co., Ltd., plans to enroll 680 participants and plans to start in November 2026, with primary completion projected for April 30, 2030. It compares RC118/RC148 combinations to Tislelizumab plus CAPOX as first-line therapy for HER2-negative, claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma.

  10. Janssen posts results of Phase 3 seltorexant trial in major depressive disorder with insomnia

    The study enrolled 757 participants and began on September 15, 2020, with primary completion on October 3, 2023. It compared seltorexant 20 mg to quetiapine XR as adjunctive therapy to antidepressants in adults and elderly patients with major depressive disorder with insomnia symptoms who had responded inadequately to antidepressant therapy.

  11. AbbVie posts results of Phase 3b TRITON study of Bimatoprost SR in glaucoma

    The trial enrolled 515 participants and completed primary data collection on August 8, 2025. It evaluated the duration of intraocular pressure-lowering effect and safety of as-needed Bimatoprost SR in participants with open-angle glaucoma or ocular hypertension not adequately managed with topical IOP-lowering medication.

  12. Harmony Biosciences posts results of Phase 3 pitolisant study in idiopathic hypersomnia

    Results for the open-label study were first posted on ClinicalTrials.gov on November 13, 2026. The completed study enrolled 119 participants and assessed the long-term safety and effectiveness of pitolisant after the double-blind randomized withdrawal phase of HBS-101-CL-010.